Press Releases
Bridgewater, NJ, Tuesday, April 18, 2023 –
Pyramid Biosciences, Inc., a privately-held, clinical-stage biotechnology company focused on developing transformative medicines for patients with cancer, and its partner GeneQuantum Healthcare (Suzhou) Co. Ltd, a privately-held biotechnology company based in China, announced data at the American Association for Cancer Research (AACR) Annual Meeting 2023 highlighting the preclinical efficacy and safety profile of GQ1010, a potential best-in-class antibody drug conjugate (ADC) targeting trophoblast cell surface antigen 2 (TROP2), across several in vitro and in vivo models.
Pyramid Biosciences to Present at the B. Riley Securities Third Annual Oncology Conference
Pyramid Biosciences To Present at the 2022 Jefferies London Healthcare Conference
Pyramid Biosciences Names Biren Amin as Chief Financial and Strategy Officer
Pyramid Biosciences Names Nushmia Khokhar, MD, as Chief Medical Officer
Pyramid Biosciences Receives Orphan Drug Designation for PBI-200 From FDA
Pyramid Biosciences Appoints Brian Lestini, MD, PhD as Chief Executive Officer
Pyramid Biosciences Expands Precision Oncology Pipeline
Pyramid Biosciences Announces First Patients Dosed in Phase 1 Clinical Program for Dermatology
Pyramid Biosciences Announces Leadership Team Expansion
Pyramid Biosciences Secures $28 Million in Funding to Accelerate Clinical Programs
